Literature DB >> 21143511

Clinical importance of the CYP2C19*17 variant allele for voriconazole.

Michael J Dolton, Andrew J McLachlan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21143511      PMCID： PMC3018036          DOI： 10.1111/j.1365-2125.2010.03801.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

Review 1.  Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.

Authors:  Alain Li-Wan-Po; Thierry Girard; Peter Farndon; Candy Cooley; James Lithgow
Journal:  Br J Clin Pharmacol       Date:  2010-03       Impact factor: 4.335

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.

Authors:  Johanna Weiss; Magdalena Maria Ten Hoevel; Jürgen Burhenne; Ingeborg Walter-Sack; Michael Marcus Hoffmann; Jens Rengelshausen; Walter E Haefeli; Gerd Mikus
Journal:  J Clin Pharmacol       Date:  2008-11-25       Impact factor: 3.126

4.  The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.

Authors:  Guo Wang; He-Ping Lei; Zhi Li; Zhi-Rong Tan; Dong Guo; Lan Fan; Yao Chen; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
Journal:  Eur J Clin Pharmacol       Date:  2008-11-04       Impact factor: 2.953

5.  Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.

Authors:  David W Denning; Patricia Ribaud; Noel Milpied; Denis Caillot; Raoul Herbrecht; Eckhard Thiel; Andrea Haas; Markus Ruhnke; Hartmut Lode
Journal:  Clin Infect Dis       Date:  2002-01-22       Impact factor: 9.079

Review 6.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 7.  Voriconazole therapeutic drug monitoring: focus on safety.

Authors:  Alessandro C Pasqualotto; Melissa O Xavier; Huander F Andreolla; Rafael Linden
Journal:  Expert Opin Drug Saf       Date:  2010-01       Impact factor: 4.250

8.  Voriconazole concentrations and outcome of invasive fungal infections.

Authors:  S Miyakis; S J van Hal; J Ray; D Marriott
Journal:  Clin Microbiol Infect       Date:  2009-10-20       Impact factor: 8.067

9.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 10.  Therapeutic drug monitoring of voriconazole.

Authors:  Roger J M Brüggemann; J Peter Donnelly; Rob E Aarnoutse; Adilia Warris; Nicole M A Blijlevens; Johan W Mouton; Paul E Verweij; David M Burger
Journal:  Ther Drug Monit       Date:  2008-08       Impact factor: 3.681
View more
  8 in total

1.  A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine.

Authors:  Mirte M Malingré; Peggy C R Godschalk; Saskia K Klein
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Authors:  Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak
Journal:  Curr Fungal Infect Rep       Date:  2015-04-16

3.  Regulatory polymorphisms in CYP2C19 affecting hepatic expression.

Authors:  Jonathan C Sanford; Yingying Guo; Wolfgang Sadee; Danxin Wang
Journal:  Drug Metabol Drug Interact       Date:  2013

4.  Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.

Authors:  Prerna K Chawla; Shweta R Nanday; Alpa J Dherai; Rajeev Soman; Rohan V Lokhande; Prasad R Naik; Tester F Ashavaid
Journal:  Int J Clin Pharm       Date:  2015-05-30

5.  Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Authors:  J Kevin Hicks; Kristine R Crews; Patricia Flynn; Cyrine E Haidar; Calvin C Daniels; Wenjian Yang; John C Panetta; Deqing Pei; Jeffrey R Scott; Alejandro R Molinelli; Ulrich Broeckel; Deepa Bhojwani; William E Evans; Mary V Relling
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

6.  Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity.

Authors:  Yassine Bouatou; Caroline Flora Samer; Kuntheavy Roseline Ing Lorenzini; Youssef Daali; Samira Daou; Marc Fathi; Michela Rebsamen; Jules Desmeules; Alexandra Calmy; Monica Escher
Journal:  AIDS Res Ther       Date:  2014-08-04       Impact factor: 2.250

7.  Frequency of the CYP2C19*17 polymorphism in a Chilean population and its effect on voriconazole plasma concentration in immunocompromised children.

Authors:  N Espinoza; J Galdames; D Navea; M J Farfán; C Salas
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

8.  Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Authors:  Y Shirasaka; A S Chaudhry; M McDonald; B Prasad; T Wong; J C Calamia; A Fohner; T A Thornton; N Isoherranen; J D Unadkat; A E Rettie; E G Schuetz; K E Thummel
Journal:  Pharmacogenomics J       Date:  2015-09-01       Impact factor: 3.245
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.